| P2093 | author name string | Sandra Cuellar | |
| | Amanda N Seddon | |
| | Christina M Haaf | |
| P2860 | cites work | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Cancer statistics, 2013 | Q27860762 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 |
| | Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer | Q33561160 |
| | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 |
| | A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer | Q34029999 |
| | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 |
| | Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer | Q35671180 |
| | A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group | Q35693076 |
| | Bevacizumab added to neoadjuvant chemotherapy for breast cancer | Q36106083 |
| | VEGF as a key mediator of angiogenesis in cancer | Q36319024 |
| | VEGF as a therapeutic target in cancer | Q36319029 |
| | Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study | Q37989260 |
| | Neoadjuvant chemotherapy in the treatment of breast cancer | Q38086907 |
| | RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 |
| | First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study | Q45258410 |
| | Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study | Q46105232 |
| | Bevacizumab plus irinotecan in recurrent glioblastoma multiforme | Q46942082 |
| | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer | Q47701435 |
| | First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. | Q53073357 |
| | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. | Q54457707 |
| | Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. | Q54534083 |
| | Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. | Q54576533 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| P304 | page(s) | 433-444 | |
| P577 | publication date | 2013-11-07 | |
| P1433 | published in | Journal of Oncology Pharmacy Practice | Q6295681 |
| P1476 | title | The life, death, and attempted rebirth of bevacizumab in breast cancer | |
| P478 | volume | 20 | |